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BACKGROUND: The enumeration of circulating tumour cells (CTC) has prognostic significance in patients with metastatic breast cancer
(MBC) and monitoring of CTC levels over time has considerable potential to guide treatment decisions. However, little is known on
CTC kinetics in the human bloodstream.
METHODS: In this study, we compared the number of CTC in both 7.5ml central venous blood (CVB) and 7.5ml peripheral venous
blood (PVB) from 30 patients with MBC starting with a new line of chemotherapy.
RESULTS: The number of CTC was found to be significantly higher in CVB (median: 43.5; range: 0–4036) than in PVB (median: 33;
range: 0–4013) (P¼0.001). When analysing samples pairwise, CTC counts were found to be significantly higher in CVB than in PVB
in 12 out of 26 patients with detectable CTC. In contrast, only 2 out of 26 patients had higher CTC counts in PVB as compared with
CVB, whereas in 12 remaining patients no significant difference was seen. The pattern of CTC distribution was independent of the
sites of metastatic involvement.
CONCLUSION: A substantial difference in the number of CTC was observed between CVB and PVB of patients with MBC. Registration
of the site of blood collection is warranted in studies evaluating the role of CTC assessment in these patients.
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Over the past 10 years, a vast body of evidence has emerged
supporting the use of circulating tumour cells (CTC) as a
promising, new prognostic factor in the clinical management of
patients with metastatic breast, colorectal and prostate cancer
(Cristofanilli et al, 2004; Cohen et al, 2008; De Bono et al, 2008).
Several studies strongly suggest an equal role in early breast cancer
(Ignatiadis et al, 2008; Pierga et al, 2008; Rack et al, 2010). In
addition, molecular characterisation of CTC has been shown to
have the potential to serve as a powerful pharmacodynamic
marker to predict tumour sensitivity to specific targeted treat-
ments (Meng et al, 2004b; de Bono et al, 2007; Attard et al, 2009).
Several approaches for the detection, enumeration and isolation
of CTCs in blood samples of patients with various types of cancer
have been developed (Mostert et al, 2009). Only the CellSearch
System (Veridex, Raritan, NJ, USA), a semi-automated system for
the immunomagnetic enrichment of CTC based on their expres-
sion of epithelial cell adhesion molecule (EpCAM), immuno-
labeling and image cytometry, has gained approval of the US Food
and Drug Administration (FDA). With this technique two or more
CTC per 7.5ml blood are detected in ca. 60% of patients with
metastatic breast cancer (MBC). Furthermore, a cutoff of five CTC
or more per 7.5ml of blood has been applied to distinguish
between good and worse prognosis in patients with MBC
(Cristofanilli et al, 2004; Hayes et al, 2006).
Previous studies have addressed several analytical sources of
variability in CTC measurements by the CellSearch System,
however, little is known about the biological variability and
kinetics of CTC in the human bloodstream (Allard et al, 2004;
Riethdorf et al, 2007; Tibbe et al, 2007; Kraan et al, 2011). Given
the physical mismatch between malignant epithelial cells, typically
having a diameter of 10–30mm, and human capillaries, on average
only 3–8mm in diameter ((Boulpaep, 2003) (p. 464)), considerable
variability in the number of CTC throughout the circulation, both
in time and space, can be anticipated. Experiments in mouse
models have shown that CTC transiently peak in the circulation
after injection in the tail vein or left cardiac ventricle, after which
they steadily increase in parallel with the development of
micrometastases in lymph nodes and/or bone marrow over several
weeks of time (Goodale et al, 2009). In line with these observations,
CTC have been shown to disappear from the bloodstream in
the majority of patients with localised breast cancer within days
after surgical removal of the primary tumour (Krag et al, 1999;
Meng et al, 2004a; Biggers et al, 2009; Sandri et al, 2010).
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sFurthermore, for most solid malignancies typical patterns of
metastasis can be predicted based on the anatomical localisation of
the primary tumour (Weiss, 1992). In a recent study evaluating the
impact of different surgical interventions for colorectal liver
metastases on CTC levels in anatomically discrete vascular compart-
ments, CTC appeared to be localised more abundantly to the hepatic
macrocirculation whereas significantly fewer enter the peripheral
circulation, suggesting that the liver and the lungs act as the major
site of retention for CTC in these patients (Jiao et al, 2009).
With this study, we wanted to investigate anticipated differences
in the occurrence, number and characteristics of CTC in different
vascular compartments of patients with breast cancer. As
quantitative cutoff values in the number of CTC are used to
distinguish between patients with good and worse prognosis,
differences in the number of CTC according to the site of blood
sampling might be of direct clinical importance. Furthermore,
differences in numbers and in characteristics of CTC in different
vascular compartments might help to gain insight into the biology
of these cells and the metastatic process.
MATERIALS AND METHODS
Patients and sample collection
Consecutive patients with MBC with either untreated metastatic
disease or progressive metastatic disease before the start of a new
line of treatment, who had an implanted central venous vascular
access system, were recruited from November 2009 till November
2010. Appropriate local ethics committee approval was obtained
and written informed consent was obtained from all patients.
CTC enumeration and characterisation
The CTC were isolated and enumerated using the CellSearch
System (Veridex) in both 7.5ml central venous blood (CVB) –
obtained from the implanted vascular device – and 7.5ml
peripheral venous blood (PVB) – obtained from an antecubital
vein. Both blood samples were drawn simultaneously in CellSave
Preservative Tubes (Immunicon Inc., Huntingdon Valley, PA,
USA), stored at room temperature and processed within 72h.
Paired samples were analysed in parallel using the CellSearch
Circulating Tumour Cell kit (Veridex) according to the manufac-
turer’s instructions. Criteria for an EpCAM positive object to be
identified as a CTC include a round-to-oval morphology, a visible
nucleus (DAPIþ), positive staining for cytokeratin and negative
staining for CD45. Each sample was analysed independently by two
readers (DP and GVdE). Questionable interpretations were
evaluated again until consensus was reached. As a measure for
the size of CTC, the geometrical area of each individual cell was
estimated based on the two longest perpendicular diameters
according to the following formula: p A/2 B/2 (with A and B
being the two longest perpendicular diameters measured on
screen) (Figure 2A).
Statistical analysis
Statistical analyses were performed using SPSS 16.0 software (SPSS
Inc., Chicago, IL, USA). A two-sided Pp0.05 was considered to be
statistically significant. Normality was tested with a Kolmogorov–
Smirnov test, assuming normality of data if P40.1. In the case of
normal distribution in all subgroups, equality of means was tested
using Student’s t-test. The Mann–Whitney U-test, Kruskal–Wallis
test or Wilcoxon Signed Ranks test were used to assess differences
between non-parametric distributed variables. Correlations be-
tween continuous variables were analysed with Spearman’s
correlation statistics. The Pearson’s w
2-test was used to assess the
relation between categorical variables.
RESULTS
A total of 30 patients were recruited into this study. This group
comprised of four patients with primary MBC and 26 patients with
MBC progressing under treatment. The median age of the patient
population was 62 (range: 40–85) years. Almost all patients had
diffuse metastatic involvement and most patients with progressive
metastatic disease were extensively pretreated with multiple lines
and types of systemic treatments. Other clinicopathological data
are summarised in Table 1.
Comparison of the number of CTC in different vascular
compartments
The number of CTC was measured in different vascular compart-
ments. In all patients CTC were assessed in CVB and PVB. Figure 1
and Table 2 represent the results. In four (13%) patients no CTC
were found in any of the vascular compartments. The median
number of CTC was 43.5 (range: 0–4036) in CVB and 33 (range:
0–4013) in PVB (P¼0.001). The CTC counts in CVB and PVB
were strongly correlated (R
2¼0.952, Po0.001). Both CTC counts
in CVB and PVB were correlated with levels of CA15.3
(R
2
CVB¼0.498, P¼0.005; R
2
PVB¼0.509, P¼0.004). Except for a
higher number of CTC in CVB in the presence of bone metastasis
(P¼0.044), no correlations between the number of CTC in either
CVB or PVB and specific sites of metastatic involvement were
observed.
Using the five CTC per 7.5ml prognostic cutoff previously
described (Cristofanilli et al, 2004) to discriminate between CTC
Table 1 Clinicopathological variables
Characteristics n¼30
Histology
Invasive ductal carcinoma 27 (90%)
Invasive lobular carcinoma 3 (10%)
Histological grade
a
I 4 (13%)
II 10 (33%)
III 16 (54%)
Hormonal status
ER and/or PR positive 25 (83%)
Negative for both 5 (17%)
HER2/neu status
b
Negative 24 (80%)
Positive 4 (13%)
Triple negative 4 (13%)
Number of organs involved
1 4 (13%)
2–5 26 (87%)
Metastatic sites
Bone 26 (87%)
Lung 10 (33%)
Liver 20 (67%)
Central nervous system 5 (17%)
Other
c 16 (53%)
Abbreviations: ER, oestrogen receptor; PR, progeterone receptor.
aTumours were
histologically graded according to the Nottingham modification of the Bloom and
Richardson histologic grading scheme.
bHER2/neu status was evaluated using
immunohistochemistry (IHC) and FISH. Samples with IHC score 0/1+ or IHC 2+
and FISH  were called negative, samples with IHC score 3+ or IHC score 2+ and
FISH+ were called positive. In two patients, HER2/neu status could not be
determined because of insufficient tissue material.
cThese sites included locoregional
involvement, pleura, peritoneum, skin, lymph nodes, adrenal gland and ovary.
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7.5ml) MBC patients, 22 out of 30 (73%) patients were CTC
positive for both CVB and PVB. There was a 100% concordance
between the results of the CVB and PVB (Table 2).
Comparison of CTC distribution patterns
We subsequently divided the 26 patients with detectable CTC in
three distinct groups based on the difference in CTC counts
between paired CVB and PVB samples, calculated as the
mathematical difference of both counts divided by their mean.
A threshold of 15% was applied to define a significant difference
based on coefficients of variation for different sources of analytical
variability of the CellSearch System reported in literature (Allard
et al, 2004; Riethdorf et al, 2007; Kraan et al, 2011). Because of
statistical considerations, patients with less than five CTC per
7.5ml in both CVB and PVB were considered to have equal counts
in both compartments. Using these criteria 12 out of 26 patients
(46%) patients had significantly higher CTC counts in CVB than in
PVB with a median percentage of difference of 59% (range:
26–108%) whereas in only two (8%) patients higher numbers were
observed in PVB with a median percentage of difference of 50%
(range: 18–82%). In the remaining 12 (46%) patients no difference
was observed between both counts (Table 2). No correlation was
found between the pattern of CTC distribution in CVB and PVB
and specific sites of metastasis in general or the prevalence of
clinically evident lung metastases in particular.
Comparison of CTC characteristics at different vascular
compartments
We compared the size of the CTC at different vascular compart-
ments. CTC were measured on screen in two dimensions and size
was estimated based on the geometrical area of an ellipse as shown
in Figure 2. Mean size of CTC in CVB and PVB of the same patient
was compared only in those patients with at least five measurable
CTC in both compartments. Overall, mean CTC area measured
77.59±4.68mm
2 in CVB and 62.28±5.02mm
2 in PVB, respectively
(Po0.001). When analysing samples pairwise, CTC measured in
CVB were significantly larger than CTC measured in PVB in 11 out
of 22 patients (50%). In the other 11 patients no statistically
significant difference in average CTC size between CVB and PVB
was observed. Furthermore, we calculated a score to estimate the
contribution of size to the numerical difference in CTC counts
between CVB and PVB as demonstrated in Figure 2B and C. When
applying a cutoff for CTC size in CVB at the maximal CTC size
measured in PVB, on average 19% (range: 0–48%) of the
Table 2 Number of CTC in CVB and PVB of patients with metastatic
breast cancer
Patient
#CTC
per
7.5ml
CVB
#CTC
per
7.5ml
PVB
Percentage
of difference
between
CVB and
PVB
a
Groups
based on
percentage
of difference
b
Contribution
score of size
1 175 87 67 1 5
20 0 N A 2 N A
37 7 4 1 6 1 1 8
4 108 42 88 1 21
51 9 1 85 2 N A
61 8 1 0 5 7 1 2 5
7 121 85 35 1 28
8 46 15 102 1 16
9 3 1 100 2 NA
10 282 138 69 1 6
11 0 0 NA 2 NA
12 49 43 13 2 NA
13 84 52 47 1 31
14 41 49  18 3  138
15 52 47 10 2 NA
16 105 59 56 1 48
17 20 6 108 1 14
18 100 109  92 N A
19 77 59 26 1 0
20 12 12 0 2 NA
21 365 363 1 2 NA
22 1 1 0 2 NA
23 5 12  82 3 0
24 2 1 67 2 NA
25 0 0 NA 2 NA
26 41 25 48 1 38
27 1 2  67 2 NA
28 0 0 NA 2 NA
29 69 69 0 2 NA
30 4036 4013 1 2 NA
Abbreviations: CTC, circulating tumour cell; CVB, central venous blood; NA, not
applicable; PVB, peripheral venous blood.
aPercentage of difference is defined as the
mathematical difference between CTC in CVB and PVB divided by their mean.
bGroups based on the percentage of difference are defined as follows: Group 1,
patients with X5 CTC per 7.5ml blood and 415% difference between CVB and
PVB with CTCCVB4CTCPVB; Group 2, patients with o5 CTC per 7.5ml blood or
patients with X5 CTC per 7.5ml blood and p15% difference between CVB and
PVB; Group 3, patients with X5 CTC per 7.5ml blood and 415% difference
between CVB and PVB with CTCCVBoCTCPVB.
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Figure 1 Logarithmic number of CTC per 7.5ml of CVB and PVB of the
30 MBC patients. Sample code: bold¼#CTCCVB4#CTCPVB (Table 2,
group 1); dashed¼#CTCCVBo#CTCPVB (Table 2, group 3);
grey¼#CTCCVB¼#CTCPVB (Table 2, group 2).
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be explained on the basis of size (Table 2; Figure 2C).
DISCUSSION
In this study, we compared the number of CTC, as assessed by the
CellSearch System, in blood samples obtained from different sites
throughout the circulation in 30 patients with MBC. We observed
significantly higher numbers of CTC in CVB than in PVB in 46% of
the patients with detectable CTC. The opposite was true in only 8%
of the patients whereas in another 46% of patients no difference
was observed at all. Given the fact that all patients included in this
study suffered from extensive metastatic involvement, the
observation of a steep concentration gradient of CTC in the blood
circulation from the central venous compartment towards the
peripheral venous compartment is in accordance with the
differences in CTC counts between portosystemic and peripheral
systemic circulations in patients with liver metastasis from
colorectal cancer reported by Jiao et al (2009).
We believe that the findings of the current study have several
important clinical and biological implications. First, although it
was generally reassuring that a 100% concordance between CVB
and PVB was observed when CTC results where dichotomised
according to the X5 CTC per 7.5ml prognostic cutoff, differing
CTC counts according to the site of blood collection might be
confounding when using decreases or increases in absolute CTC
numbers as a surrogate endpoint for the assessment of treatment
efficacy in cancer patients as proposed by several authors (Smith
et al, 2000; Pachmann et al, 2008; Molife et al, 2011). From this
perspective, comparison of CTC levels over the course of treatment
would only render reliable information if blood samples were
obtained from the same vascular site. This also implies the need of
recording the site of blood sampling on every occasion. In
addition, as this was only a small study it cannot be excluded that
in larger patient series discordant results according to the X5 CTC
per 7.5ml prognostic cutoff will be observed.
Second, the observed difference in CTC numbers between CVB
and PVB might also provide direct insight into CTC biology in the
human circulation. As most patients included in this study had
multiple systemic metastases – draining directly to the CVB
compartment – and metastases in the distal arm – draining to the
antecubital vein from which the PVB was drawn – were not seen,
the observation of higher CTC numbers in the CVB compared with
the PVB suggests an important filtering function for the lung
microvascular system in these patients. Although this might not
apply for CTC shedding from lung metastases, we were not able to
show any association between the CTC distribution pattern and the
presence or absence of clinically evident lung metastases, probably
because almost all patients with lung metastases also suffered from
diffuse systemic disease. Only one patient was diagnosed with
isolated lung metastases. In this patient one CTC was observed,
both in CVB and PVB.
Taking into account that the average cardiac output of a resting
adult is B5l per min and assuming that the difference in CTC
counts between CVB and PVB is constant over time, one could
calculate the total number of CTC filtered by the lungs in 24h. For
instance for patient 1 in Table 2 presenting with 175 CTC per
7.5ml in CVB and 87 CTC per 7.5ml in PVB, this would mean that
a total of 85 million CTC would be filtered out by the lungs in
1 day’s time. The cumulative entrapment of CTC in the
microcirculation of the lungs might potentially provide an
explanation for some radiologically unexplained respiratory
distress syndromes frequently observed in end-stage cancer
patients (Roberts et al, 2003). The observation of intravascular
tumour cells in microvascular blood samples in patients suggested
to suffer from so-called ‘lymphangitic’ carcinomatosis is in
keeping with this observation (Masson et al, 1989).
Third, to address the extent to which size filtration might
contribute to the observed differences in more depth, we compared
the size of CTC visualised by the CellSearch System in CVB and
PVB of the same patient. Although in 50% of the patients CTC in
CVB were significantly larger than CTC in PVB, these size
differences could only explain 0–48% of the difference in CTC
counts observed between both compartments.
Last, the lung is a very frequent site of metastatic growth in
patients with MBC. Animal models have suggested that a primary
intravascular location of breast cancer cells occurs as a mode of
intravascular growth before extravasation (Wong et al, 2002). Our
observation of a high degree of cancer cell retention in the lung,
suggests at least a stochastic advantage for the lung to harbour
efficient metastatic growth. Again, this is in keeping with the
observations made by Jiao et al (2009) explaining the high
propensity of colorectal cancer to seed to the liver and lungs.
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Figure 2 Comparison of CTC size in CVB and PVB. (A) Calculation method for the area of an individual CTC as a measure for size. (B) Frequency curves
of CTC sizes in CVB and PVB for one illustrative patient. A cutoff for size in CVB was applied at the maximal size measured in PVB. (C) Formula for the
calculation of the ‘contribution score’ for size to the numerical difference in CTC between CVB and PVB.
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contradiction with any superimposed selective and organ-specific
homing model that, beside size filtration, might also account in
part for the loss of (subpopulations) of CTC throughout the
circulation (Mu ¨ller et al, 2001; Glinskii et al, 2005; Nguyen et al,
2009). From this perspective, it will be of interest to compare
molecular profiles of CTC harvested at different sites in the blood
circulation with regard to cell adhesion pathways, epithelial-
mesenchymal transition and stem cell characteristics, which is the
subject of an ongoing study.
A limitation of the current study is the variety of lines and
types of treatment the included patients previously had received.
Rather than representing one cell population, CTC are considered
to form a heterogeneous cell population and different treatments
might have discrete effects on specific CTC subpopulations
(Meng et al, 2004b; Aktas et al, 2009; Van Der Auwera et al,
2010). Also, the fact of most patients suffering from diffuse
metastatic disease makes it very difficult to draw firm conclusions
on how CTC circulate or rather shed in the blood stream in
relation to specific sites of disease involvement. To address these
questions properly, larger studies including more uniform, less
extensively pretreated patient populations and patients with
metastatic disease confined to either the lungs or the systemic
circulation, must be carried out.
In conclusion, we observed statistically different numbers of
CTC in CVB and PVB in 14 of 26 (54%) patients with MBC. As
quantitative assessment of CTC is proposed for the evaluation of
treatment efficacy in patients with MBC, registration of the site of
blood collection is warranted in clinical practice and studies
evaluating the role of CTC assessment to be able to draw correct
conclusions.
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